Company DNA profile
Eli Lilly and Company
Trading as Eli Lilly
Eli Lilly and Company is a pharmaceutical company that develops drugs against diabetes, obesity and other chronic diseases.
- Ref.
- FG-0090
- Delivered
- 29 Sep 2026
- Profile type
- Extended profile
- Sector
- Healthcare
- Headquarters
- Indianapolis, USA
- Employees
- 50,000
- Website
- lilly.com
Profile completion rate 62 fields completed out of a total of 119
Every company is unique. Some organizations publish extensive information about their activities, while others maintain a limited public footprint. In addition, certain profile sections may not be relevant to a specific company. As a result, a 100% profile completion rate is neither expected nor required.
52% completion rate, by chapter:
- 1 Core identity, 55% completed
- 2 Contact & location, 88% completed
- 3 Business activity, 75% completed
- 4 Corporate structure, 36% completed
- 5 Executive leadership, 75% completed
- 6 Financial profile, 6% completed
- 7 Ecosystem & strategy, 47% completed
- 8 Human capital, 100% completed
- 9 Innovation & R&D, 22% completed
- 10 Business model, 80% completed
- 11 Fundraising, 50% completed
- 12 Valuation, 73% completed
Every field the Company DNA defines counts once: 119 in total. A list counts as one field, whatever its length. The rate is the share of fields that contain data. Profile richness and credit consumption
Evidence Foundation428 citations · 238 domains
| Metric | Value |
|---|---|
| Evidence Citations | 428 |
| Unique Articles (URLs) | 396 |
| Source Domains | 238 |
| Coverage Period | Feb 2019 – Sep 2026 |
| Community Recognition | n/a |
| Evidence Strength Index | n/a |
Evidence Strength Index = 0.35 × citation score + 0.25 × diversity score + 0.25 × recognition score + 0.15 × freshness score. Citation and diversity scores reach 100 at 200 citations and 50 domains (log scale); freshness is judged on the newest source at the delivery date.
6/11 items55%
- 1.1Company name
- Eli Lilly and Company
- 1.2Commercial name
- Eli Lilly
1.3Brands 20
| Evidence | ||
|---|---|---|
| Verzenio | cancer treatment | |
| Mounjaro | diabetes treatment | |
| Zepbound | obesity treatment | |
| Jardiance | diabetes treatment | |
| Trulicity | diabetes treatment | |
| Humalog | diabetes treatment | |
| Humulin | diabetes treatment | |
| Taltz | immunology treatment | |
| Olumiant | immunology treatment | |
| Cialis | erectile dysfunction treatment | |
| Alimta | cancer treatment | |
| Forteo | osteoporosis treatment | |
| Foundayo | weight loss treatment | |
| Retatrutide | obesity treatment | |
| Lormalzi | Alzheimer's disease-modifying drug | |
| Jaypirca | lymphoma treatment | |
| Elizabeth Arden | cosmetics | |
| Tirzepatide | diabetes management drug | |
| Yurpeak | diabetes management drug | |
| Emgality | migraine treatment |
- 1.6Legal form
- Inc.
- 1.10Year founded
- 1876
- 1.11Company history
- Eli Lilly was founded in Indianapolis in 1876 and incorporated in 1901. Eli Lilly was founded by Civil War veteran Eli Lilly. The chemist-founded operation initially focused on malaria treatments and antibiotics.
7/8 items88%
2.1Headquarters address
- 2.1.1Street address
- Lilly Corporate Center
- 2.1.2City
- Indianapolis
- 2.1.3State / province
- Indiana
- 2.1.4Postal code
- 46285
- 2.1.5Country code
- US
- 2.2Country
- USA
- 2.3Website
- lilly.com
9/12 items75%
- 3.1Sector
- Healthcare
- 3.3Business description
- Eli Lilly and Company is a pharmaceutical company that develops drugs against diabetes, obesity and other chronic diseases.
- 3.4Products & services
- Mounjaro, Zepbound, Foundayo, Strattera, Tiapride, Flomoxef Sodium, Orforglipron, Tirzepatide, Retatrutide, Donanemab
3.5Recent product launches 4
| Evidence | |||
|---|---|---|---|
| Retatrutide | 1 Jan 2027 | GLP-1 weight loss pill | |
| Foundayo | 2026 | GLP-1 weight loss pill | |
| Mounjaro | 2025 | weight-loss drug | |
| Donanemab | Undated | Alzheimer’s drug |
- 3.6Countries of operation
- United States, China, United Kingdom, Germany, Romania, Bulgaria, Serbia, Croatia, Slovenia, Bosnia and Herzegovina, India, Japan, Puerto Rico, Israel, Mexico
3.7Industrial footprint
3.7.2Facility types 3
- manufacturing hub
- factory
- manufacturing campus
3.7.3Key locations 22
- Indianapolis, Indiana
- Alzey, Rhineland-Palatinate
- San Diego, California
- Houston
- Lebanon, Indiana
- Upper Macungie Township
- Goochland County, Virginia
- Carolina, Puerto Rico
- Lehigh Valley
- Suzhou, Jiangsu province
- Texas
- North Carolina
- Wisconsin
- Pennsylvania
- Huntsville
- Telangana
- Hyderabad
- Huntsville, Alabama
- Kobe
- Limestone County
- Raanana
- Virginia
3.8Distribution network
3.8.1Countries 2
- United States
- United Kingdom
3.8.3Distributors 5
- GoodRx
- MedPal
- DKSH
- Cipla
- Amazon
4/11 items36%
4.4Subsidiaries 3
| Evidence | ||
|---|---|---|
| Elanco Animal Health | United States | |
| Eli Lilly Interamerica | Not found | |
| Eli Lilly Japan | Japan |
4.6Sold businesses 1
| Evidence | |||||
|---|---|---|---|---|---|
| Branchburg, New Jersey biopharmaceutical production facility | Celltrion | 24 Sep 2025 | $330M | Sale of US plant |
4.7Recent M&A and partnerships 14
| Evidence | ||||||
|---|---|---|---|---|---|---|
| 12 Sep 2026 | Merger | AtaiBeckley | $2.8B | fast-acting therapeutics | Completed | |
| 16 Jul 2026 | Acquisition | AtaiBeckley | $2.8B | Entry into psychedelic mental health treatments | Completed | |
| 22 Jun 2026 | Investment | BioArctic | $800M | Brain delivery technology | Announced | |
| 26 May 2026 | Acquisition | Curevo | $1.5B | Expand into vaccine development | Announced | |
| 26 May 2026 | Acquisition | three vaccine developers | Not found | expansion into new therapeutic areas | Announced | |
| 21 Apr 2026 | Acquisition | Kelonia Therapeutics | $7B | Expansion into oncology pipeline with early clinical phase lentiviral in vivo chimeric antigen receptor T-cell (CAR-T) therapy | Announced | |
| 14 Apr 2026 | Acquisition | CrossBridge Bio | $300M | Expand pipeline in oncology and immunology | Announced | |
| 31 Mar 2026 | Acquisition | Centessa Pharmaceuticals | $7.8B | Expansion into neuroscience and orexin-based therapies for neurological disorders | Announced | |
| 17 Jun 2025 | Acquisition | Verve Therapeutics | $1.3B | Cardiovascular gene editing | Pending | |
| 27 May 2025 | Acquisition | SiteOne Therapeutics | $1B | Pain pipeline expansion | Announced | |
| 13 Jan 2025 | Acquisition | Scorpion Therapeutics | Not found | Expansion into intestinal diseases | Completed | |
| 9 Jul 2024 | Acquisition | Morphic Holding | $3.2B | expansion of immunology portfolio | Completed | |
| 8 Jul 2024 | Acquisition | Morphic Therapeutic | $3.2B | Access to experimental drug for inflammatory bowel diseases | Completed | |
| 4 Oct 2023 | Acquisition | POINT | $1.4B | Radiopharma acquisition | Completed |
4.8Recent legal structure changes 1
| Evidence | |||
|---|---|---|---|
| 11 Mar 2019 | Spin-off | Elanco Animal Health becomes independent |
6/8 items75%
5.1CEO
David A. Ricks
Chair and CEO
5.2CEO announcements 3
| Evidence | |||
|---|---|---|---|
| 21 Sep 2026 | 700,000 new elderly patients join, Eli Lilly dominates 70% | Since Medicare started covering obesity drugs in July | |
| 18 Apr 2026 | Weight-loss drugs may eventually reach only about 50 per cent of the overweight and obese people who could benefit from them | Due to complexities of healthcare systems and financial constraints | |
| 6 Nov 2025 | Deal with Trump administration to slash weight loss drug prices | Eli Lilly CEO David Ricks said the deal marks "a pivotal moment in U.S. health care policy and a defining milestone for Lilly" |
5.3Other executives 9
| Evidence | |||||
|---|---|---|---|---|---|
| Francisco Ramírez-Valle | Senior Vice President, Immunology Discovery | Immunology Discovery | 2026 | High | |
| Mike Mason | Lilly Diabetes and Obesity President | Diabetes and Obesity | 2023 | High | |
| Kenneth Custer | Vice-President | Research and Development | 2026 | High | |
| Tomoko Mizuno | Outside Director | Board of Directors | 2024 | High | |
| Anamaria Simion | General Manager for Bulgaria and Serbia | Human Resources / International | 2026 | High | |
| Lucas Montarce | Executive Vice President, Chief Financial Officer | Finance / Executive Committee | 2024 | High | |
| Anat Ashkenazi | CFO | Finance | 2024 | High | |
| Thomas J Fuchs | Chief Artificial Intelligence (AI) Officer | Not found | 2024 | High | |
| Diogo Rau | Chief Information and Digital Officer | Not found | 2025 | High |
6.4Recent capex investments 22
| Evidence | |||
|---|---|---|---|
| 21 Apr 2026 | $7B | Acquisition of Kelonia Therapeutics | |
| 30 Mar 2026 | $2.7B | AI drug discovery | |
| 30 Mar 2026 | $6.3B | Acquisition of Centessa Pharmaceuticals | |
| 15 Mar 2026 | $3B | investment in China | |
| 12 Mar 2026 | $126M | Japan plant investment | |
| 4 Feb 2026 | $6B | Huntsville plant investment | |
| 30 Jan 2026 | $3.5B | manufacturing plant in Pennsylvania | |
| 30 Jan 2026 | $55B | global investments | |
| 30 Jan 2026 | $2.8B | facility in Concord, North Carolina | |
| 30 Oct 2025 | $1.2B | Puerto Rico expansion | |
| 6 Oct 2025 | $1B | Telangana investment | |
| 6 Oct 2025 | $1B | investment in Hyderabad | |
| 23 Sep 2025 | $6.5B | Texas manufacturing plant | |
| 16 Sep 2025 | $5B | manufacturing plant in Virginia | |
| 26 Feb 2025 | $27B | four new manufacturing sites in the U.S. | |
| 26 Feb 2025 | $27B | manufacturing investment | |
| 16 Oct 2024 | $200M | China expansion | |
| 4 Oct 2024 | $4.5B | research and manufacturing facility | |
| 3 Oct 2024 | $4.5B | new factories | |
| 12 Sep 2024 | €1.6B | expansion in Cork and Limerick sites | |
| 24 May 2024 | $5.3B | Indiana plant expansion | |
| 24 May 2024 | $9B | new facility for weight loss drug Zepbound |
9/19 items47%
- 7.3Key competitors
- Novo Nordisk
7.6Partners 24
| Evidence | ||
|---|---|---|
| Insilico Medicine | co-development deal | |
| GoodRx | partnership to offer Foundayo and Zepbound KwikPen for self-pay patients | |
| Bristol Myers Squibb | technology partnership to integrate AI in drug development | |
| Incyte | technology partnership to integrate AI in drug development | |
| NVIDIA | five-year, $1 billion partnership to create a Co-Innovation AI Lab | |
| Innovent Biologics | strategic collaboration to advance novel medicines in oncology and immunology | |
| Ascidian Therapeutics | global research collaboration and licensing agreement to discover and develop therapies for undisclosed monogenic kidney diseases | |
| DKSH | strategic partnership to sell, promote, and distribute Lilly's pharmaceutical products across Hong Kong SAR and Macau SAR | |
| Neuroaxis Clinic | partnership dedicated to the early detection of Alzheimer's disease | |
| Repertoire Immune Medicines | immunology deal | |
| Cipla | marketing Mounjaro under a new brand name for India | |
| Amazon | direct-to-consumer delivery of Zepbound and other drugs | |
| insitro | collaboration to develop machine learning models for small molecule discovery | |
| Samsung Biologics | open innovation hub for emerging biotechnology companies in Korea | |
| Isomorphic Labs | apply artificial intelligence (AI) in medical research | |
| MrMed | strategic partnership to expand access to affordable GLP-1 medications in India | |
| Semmelweis University | strategic partnership to start initiations in patient care, professional training, residential health and data controlled healthcare | |
| Hanmi Pharm | licensing and research agreement | |
| Haisco Pharmaceutical Group | licensing and research agreement | |
| Remedium | landmark deal | |
| Innovent | partnership to develop mazdutide | |
| Cambrex | agreement to advance medicine manufacturing | |
| Xtalpi | novel drug deal | |
| EVA Pharma | agreement to extend access to baricitinib |
7.7Corporate investments 14
| Evidence | |||||
|---|---|---|---|---|---|
| BigHat Biosciences | 25 Sep 2026 | $75M | Series C | Not found | |
| Moonwalk Biosciences | 8 Sep 2026 | $70M | Series B | Not found | |
| Leal Therapeutics | 24 Aug 2026 | $30M | Series A | Not found | |
| National Resilience | 30 Jul 2026 | $750M | Strategic corporate investment | Not found | |
| Abridge | 12 Jun 2026 | Not found | Strategic investment | Not found | |
| NewLimit | 10 Jun 2026 | $435M | venture investment | Not found | |
| Dualitas | 16 Sep 2025 | $65M | Series A financing | advance a portfolio of next-generation bispecific antibodies | |
| Verve Therapeutics | 17 Jun 2025 | $1.3B | acquisition | focused on Verve's PCSK9 base-editing program | |
| Haya Therapeutics | 8 May 2025 | $65M | Series A financing | to advance its investigational precision RNA-guided regulatory genome targeting therapeutics | |
| Solu Therapeutics | 10 Apr 2025 | $41M | Series A financing | development of therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas | |
| Crossbow Therapeutics | 18 Mar 2025 | $77M | Series B | Not found | |
| Augustine Therapeutics | 26 Jun 2024 | €17M | Series A financing | development of new molecules for the treatment of neurodegenerative and cardiometabolic diseases | |
| Alto Neuroscience | 27 Nov 2023 | $45M | Series A | AI-driven biomarker platform for precision medicines in neuroscience | |
| Volastra Therapeutics | Undated | Not found | Not found | Not found |
7.8Innovation & startup partnerships 6
| Evidence | ||||
|---|---|---|---|---|
| Insilico Medicine | AI-powered drug discovery platform | co-development deal to accelerate the discovery and development of novel therapeutics | 29 Mar 2026 | |
| Biotech Collaboration Model | early-stage innovation | accelerate early-stage drug development through partnerships with biotechnology firms | 6 Feb 2026 | |
| Co-Innovation AI Lab | AI-powered drug discovery platform | five-year, $1 billion partnership to create a Co-Innovation AI Lab | 12 Jan 2026 | |
| NVIDIA and Eli Lilly AI Co-Innovation Lab | AI-powered drug discovery platform | five-year, $1 billion partnership to create a Co-Innovation AI Lab | 12 Jan 2026 | |
| insitro | machine learning models for small molecule discovery | collaboration to develop machine learning models for small molecule discovery | 9 Sep 2025 | |
| Cambrex | biotech manufacturing | to support Lilly's mission to enable external biotech collaborators to expedite their product development | 3 Oct 2024 |
7.9Top linked entities
7.9.2Organizations 22
- Novo Nordisk
- Insilico Medicine
- GoodRx
- Bristol Myers Squibb
- Incyte
- NVIDIA
- Innovent Biologics
- Ascidian Therapeutics
- DKSH
- Neuroaxis Clinic
- Hanmi Pharm
- Haisco Pharmaceutical Group
- National Resilience
- Crossbow Therapeutics
- Moonwalk Biosciences
- Leal Therapeutics
- BigHat Biosciences
- Volastra Therapeutics
- NewLimit
- Abridge
- Andreessen Horowitz
- EVA Pharma
7.9.4Locations 4
- United States
- Germany
- UK
- India
7.10Recent contracts awarded 2
| Evidence | ||||
|---|---|---|---|---|
| LY-CoV555 and LY-CoV016 combination monoclonal antibody therapeutic | US government | 22 Feb 2021 | $2.52B | |
| LY-CoV555 COVID-19 therapeutic drug treatment | US government | 27 Jan 2021 | $625M |
7.11Complaints & convictions 5
| Evidence | ||||
|---|---|---|---|---|
| 22 Sep 2026 | Civil Litigation | Florida Attorney General | lawsuit against Eli Lilly, Novo Nordisk, and Sanofi over insulin pricing | |
| 21 Jul 2026 | Civil Litigation | Novo Nordisk | Novo Nordisk sues Eli Lilly for misleading GLP-1 advertising | |
| 5 Jan 2026 | Civil Litigation | Indiana Attorney General | lawsuit against Eli Lilly to lower insulin prices | |
| 13 Aug 2025 | Civil Litigation | Texas | alleged kickback scheme involving Mounjaro and Zepbound | |
| 1 Apr 2025 | Civil Litigation | Empower Pharmacy | Eli Lilly sued Empower Pharmacy for allegedly selling 'knockoff' versions of its weight loss and diabetes drugs |
- 7.13Major risks
- regulatory risks, pricing pressure, reimbursement decisions, geopolitical tensions
4/4 items100%
- 8.1Number of employees
- 50,000
8.2Recent job creations / hires 6
| Evidence | |||
|---|---|---|---|
| Not found | 150 | engineering, science, quality assurance, operations | |
| between 2027 and 2030 | 2,000 | construction | |
| Not found | 400 | engineers, scientists, operating personnel, lab technicians | |
| 2024 | 900 | engineers, scientists, operating personnel, lab technicians | |
| over six years | 450 | manufacturing | |
| by 2032 | 3,000 | construction |
8.3Recent mass layoffs 1
| Evidence | |
|---|---|
| Reduction of planned expansion in Germany from 1,000 to 500 employees |
8.4Recent open jobs 5
| Evidence | |||
|---|---|---|---|
| Associate Director – Project Management – Foundry Operational Readiness | Project Management | Lebanon, Indiana, United States of America | |
| Clinical Data Management | Clinical Data Management | Bangalore | |
| Lead - Operator - LFD | Operations | Indianapolis | |
| Assistant Chief, Lilly Fire Rescue HSE | Not found | Indianapolis | |
| Associate Director – Medical Science Liaison | Medical Affairs | Upstate New York |
2/9 items22%
9.5R&D centers 5
| Evidence | ||
|---|---|---|
| China | Digital health and AI | |
| Singapore | Digital Health | |
| Songdo, Incheon | Genetic medicine and RNA | |
| Lebanon, Indiana | Not found | |
| Philadelphia | Not found |
- 9.6Tech stack
- AI, NVIDIA GPUs, supercomputer
4/5 items80%
- 10.1Revenue model types
- B2B
10.2Revenue streams 5
| Evidence | ||
|---|---|---|
| GLP-1 drugs | weight loss and diabetes treatments | |
| cardiometabolic health | Not found | |
| neuroscience | Not found | |
| cancer | Not found | |
| immunology | Not found |
- 10.3Sales channels
- Direct Sales Team, Direct / Online
- 10.4Target customer segments
- patients, hospitals, Specialty Clinics
2/4 items50%
- 11.2Funding stage
- Public
- 11.4Key investors
- Alpha Wave, YK Bioventures, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, Future Ventures, The General Partnership, Index Ventures, General Catalyst, Andreessen Horowitz, ADP Ventures, Paychex, Scale Venture Partners, QuantumLight, SemperVirens, Quiet Capital, Avid Ventures, Catalio Capital Management, LG Technology Ventures, Sigmas Group, Sofinnova Partners, Earlybird Venture Capital, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest, Schroders Capital, Asabys Partners, Charcot-Marie-Tooth (CMT) Research Foundation, AdBio Partners, V-Bio Ventures, PMV, VIB New Ventures, Gemma Frisius Fund
8/11 items73%
12.1Latest valuation
- 12.1.1Amount
- $1000B
- 12.1.2Currency
- USD
- 12.1.3Valuation date
- 21 Nov 2025
- 12.1.4Valuation type
- Market Capitalization
12.2Valuation history 3
| Evidence | |||
|---|---|---|---|
| 23 Mar 2026 | $684B | Market Capitalization | |
| 6 Jan 2026 | $960B | Market Capitalization | |
| 21 Nov 2025 | $1000B | Market Capitalization |
12.3Public market metrics
- 12.3.1Market cap
- $1000B
- 12.3.5Currency
- USD
- 12.3.6As of
- 21 Nov 2025
57 of 119 items